Avoidable waste of research related to outcome planning and reporting in clinical trials by Yordanov, Youri et al.
RESEARCH ARTICLE Open Access
Avoidable waste of research related
to outcome planning and reporting
in clinical trials
Youri Yordanov1,2,3,4* , Agnes Dechartres1,4,5,6, Ignacio Atal1,4, Viet-Thi Tran1,4, Isabelle Boutron1,4,5,6,
Perrine Crequit1,4 and Philippe Ravaud1,4,5,6,7
Abstract
Background: Inadequate planning, selective reporting, and incomplete reporting of outcomes in randomized
controlled trials (RCTs) contribute to the problem of waste of research. We aimed to describe such a waste and to
examine to what extent this waste could be avoided.
Methods: This research-on-research study was based on RCTs included in Cochrane reviews with a summary of
findings (SoF) table. We considered the outcomes reported in the SoF tables as surrogates for important outcomes
for patients and other decision makers. We used a three-step approach. (1) First, in each review, we identified, for
each important outcome, RCTs that were excluded from the corresponding meta-analysis. (2) Then, for these RCTs,
we systematically searched for registrations and protocols to distinguish between inadequate planning (an important
outcome was not reported in registries or protocols), selective reporting (an important outcome was reported in
registries or protocols but not in publications), and incomplete reporting (an important outcome was incompletely
reported in publications). (3) Finally, we assessed, with the consensus of five experts, the feasibility and cost of
measuring the important outcomes that were not planned. We considered inadequately planned or selectively or
incompletely reported important outcomes as avoidable waste if the outcome could have been easily measured at no
additional cost based on expert evaluation.
Results: Of the 2711 RCTs included in the main comparison of 290 reviews, 2115 (78%) were excluded from at least
one meta-analysis of important outcomes. Every trial contributed to 55%, on average, of the meta-analyses of
important outcomes. Of the 310 RCTs published in 2010 or later, 156 were registered. Inadequate planning affected
79% of these RCTs, whereas incomplete and selective reporting affected 41% and 15%, respectively. For 63% of RCTs,
we found at least one missing important outcome for which the waste was avoidable and for 30%, the waste was
avoidable for all important outcomes.
Conclusions: Most of the RCTs included in our sample did not contribute to all the important outcomes in
meta-analyses, mostly because of inadequate planning or incomplete reporting. A large part of this waste of research
seemed to be avoidable.
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Background
Clinical trials are only as credible as their outcomes, so to
inform decision-making appropriately, randomized con-
trolled trials (RCTs) must evaluate the outcomes that are
most important to patients and their caregivers [1–8].
Failure to do so could contribute to the overwhelming
problem of waste in research [9–16]. Waste of research
related to inadequate outcome planning, selective
reporting, and incomplete reporting of outcomes in RCTs
prevents patients and their physicians from making
well-informed decisions, with potential serious con-
sequences if ineffective or harmful treatments are pro-
moted [9, 12–14, 17, 18].
Therefore, when planning an RCT, researchers are ex-
pected to measure all important outcomes [9]. However,
previous studies found that less than one-fifth of diabetes
RCTs and less than one-quarter of cardiovascular trials
considered patient-important outcomes as their primary
outcomes [19, 20]. Instead, researchers frequently rely on
surrogates as a proxy for final patient-important outcomes
because these outcomes allow for smaller, faster, and thus,
cheaper clinical trials [21–24]. However, surrogates can be
misleading, because they may show exaggerated treatment
effect sizes or even an apparent benefit of harmful treat-
ments, as was the case for the use of antiarrhythmic drugs
after myocardial infarction, which led to the deaths of sev-
eral thousand patients decades ago [25–28].
Selective reporting has been repeatedly described as an-
other important issue affecting RCT outcomes [29–32].
Outcome reporting bias arises when outcomes are select-
ively reported based on the nature and direction of the re-
sults [33]. In a recent study, the median proportion of
RCTs with discrepancies between registered and published
primary outcomes was 31% [34]. Statistically significant
outcomes were 2 to 4 times more likely to be
reported in publications than non-significant ones,
which biases the available body of evidence toward
more positive results [30].
Similarly, a median of 31% to 50% of efficacy outcomes
were found to be incompletely reported in RCT articles
[29, 35, 36]. With incomplete reporting of outcomes,
outcomes cannot be included in meta-analyses, which
poses a serious threat to the usability of trial results: not
including all available results in meta-analyses can lead
to a truncated vision of the overall body of evidence.
The purpose of this study was to describe the waste of
research related to inadequate planning, selective report-
ing, or incomplete reporting of outcomes in RCTs and
to examine to what extent this waste could be avoided.
For this, we addressed the following specific questions:
(1) What proportion of RCTs are excluded from
meta-analyses due to outcome reasons? (2) Were the ex-
clusions related to inadequate planning, selective report-
ing, or incomplete reporting? (3) Was it feasible to
measure the missing outcomes at the planning stage,
and at what cost?
Methods
We performed a research-on-research study based on
RCTs included in Cochrane systematic reviews. We used
the outcomes reported in the summary of findings (SoF)
tables of reviews as surrogates for important outcomes, be-
cause Cochrane systematic review SoF tables should in-
clude the most important outcomes for patients and other
decision makers, whether they are available in RCTs or not
[7]. This study used a three-step approach. (1) First, for all
important outcomes, we identified the RCTs that were in-
cluded in the Cochrane reviews but excluded from the cor-
responding meta-analyses because the important outcome
was missing. (2) Then, we systematically searched for trial
registrations and protocols to distinguish between the out-
comes that were not planned (not included in registries or
protocols, i.e., inadequate planning) and outcomes that
were planned. For the planned outcomes, we distinguished
between those that were adequately reported and those
that were incompletely reported (poor reporting) or not
reported (selective reporting). (3) Finally, we assessed, via
expert consensus, the feasibility and cost of measuring the
outcomes that were not planned.
The eligibility criteria at each phase of the study are
summarized in Additional file 1.
Identification of RCTs excluded from meta-analyses
Data sources
We obtained data from all Cochrane systematic reviews
published between March 2011 and September 2014.
They were provided by the Cochrane Collaboration edi-
torial unit as XML files and contained all information
reported by the review authors in RevMan, the software
developed by the Cochrane Collaboration for preparing
and maintaining systematic reviews [37]. Cochrane sys-
tematic reviews of interventions are organized by com-
parisons of two treatment groups. Meta-analyses are
then performed for one or more outcomes within each
comparison. Cochrane reviewers are encouraged to
present an SoF table summarizing information on the
quality of evidence and treatment effect magnitude
(from the meta-analysis result) for the most important
outcomes (see example in the review by Mocellin and
colleagues [38]) [7]. According to the Cochrane collabor-
ation, these outcomes should be important to all re-
search end users, that is, patients and other decision
makers [7]. These outcomes include a “wide variety of
events such as mortality and major morbidity (such as
stroke and myocardial infarction); however, they may
also represent frequent minor and rare major side ef-
fects, symptoms and quality of life, burdens associated
with treatment, and resource issues (costs)” [7].
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Selection of relevant Cochrane systematic reviews
Using R 3.1.1 and the XML package, one of us (IA) re-
moved from the set of reviews provided by the Cochrane
Collaboration withdrawn Cochrane reviews and then
identified all reviews of RCTs with an SoF table. We ex-
cluded reviews that included observational studies and
those including only RCTs published before 2007 be-
cause we focused on recent RCTs. From all eligible
Cochrane reviews, using a random number generator,
we drew a random sample of 300 for an in-depth evalu-
ation but excluded a further 10 reviews because their
SoF tables mixed various interventions, which resulted
in a final sample of 290 Cochrane reviews.
Identification of important outcomes
We considered outcomes reported in the SoF table as a
surrogate for important outcomes. Therefore, we manu-
ally identified and extracted all outcomes reported in the
SoF tables. Most reviews had a single SoF table, but
some had several tables, corresponding to different com-
parisons. In this case, we focused on the main compari-
son as acknowledged by the authors. If the main
comparison was not reported by the review authors or if
various comparisons were reported in the same SoF
table, we selected the comparison with the most out-
comes and included the largest number of RCTs. If the
SoF table reported various interventions (e.g., presented
three meta-analyses of different outcomes for three
different interventions), the review was excluded.
We classified each outcome as follows: mortality, other
clinical event (e.g., myocardial infarction or stroke), thera-
peutic decision (e.g., transfusion), function (e.g., disability),
pain, quality of life, adverse events or side effects (identified
as such by the review authors), physiological variable (e.g.,
blood pressure or weight), biological variable (e.g., choles-
terol levels), radiological variable (e.g., measure of joint
space), compliance (e.g., discontinuation for any reason),
process (e.g., duration of surgical procedure), resource use
(hospitalization), cost-effectiveness, and satisfaction with
care [39].
Identification of RCTs excluded from meta-analyses
For each review and for each important outcome, we
identified all RCTs excluded from the outcome in the
corresponding meta-analysis. To do so, by using the
reference list of all studies included in the Cochrane
review, we first identified all RCTs available for the
selected comparison by extracting all RCTs included in
any meta-analysis reported for this comparison. Then,
for each of these RCTs, we manually evaluated whether
they contributed to the meta-analysis of each important
outcome by screening RCTs included in the correspond-
ing meta-analysis.
Evaluation of the reason for a missing outcome
We a priori hypothesized that the exclusion of an RCT
from a meta-analysis for outcome reasons could be related
to inadequate planning (i.e., the outcome was not planned
to be measured), selective reporting (i.e., the outcome was
planned but not reported in the publication), or incom-
plete reporting (i.e., the outcome was reported in the pub-
lication but not in a way that allowed for pooling of data).
To distinguish among inadequate planning, selective
reporting, or incomplete reporting, for each RCT ex-
cluded from at least one meta-analysis, we screened the
data available in Cochrane reviews and systematically
searched for trial registration and/or protocols.
We focused on RCTs published in 2010 or later to
maximize the chance of identifying trial registration
or protocols.
Search for RCT registration and protocols
For each RCT, we individually assessed all available re-
ports and information. To do that, we extracted the refer-
ences identified from the “References to studies included
in this review” section of the Cochrane reviews. One of us
(YY) retrieved all the articles, conference abstracts, reports
etc. related to the identified RCT. We screened all articles
for any information regarding registration (name of trial
registry and/or registration number) and/or protocol avail-
ability. When no reference to a trial registration was
found, we used the following approach:
1. We searched the full text of the Cochrane review
for any information regarding trial registration.
2. If no information was found, we searched the
World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP). Also,
according to the author’s affiliation, we searched
the local registry if not part of the WHO ICTRP.
We used the article title, the first and last author’s
name as author or as investigator, or the author’s
affiliation as search keywords.
3. If no information was found, we searched Google
with the publication title and keywords regarding
registration (e.g., registry, registration, NCT etc.).
4. If no information was found, we contacted the
corresponding author to ask whether the trial was
registered and whether a protocol was available.
Evaluation of the reason for the missing outcome
For each identified RCT, one of us (YY) classified each
missing outcome into one of the following five categories:
1. Inadequate planning
 The outcome was not planned according to the
protocol or the registry entry. It was not
reported in the available trial reports.
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2. Selective reporting
 The outcome was planned according to the
protocol or the registry entry but was not
reported in the available trial reports.
3. Incomplete reporting
 The outcome was planned according to the
protocol or the registry entry and was reported in
the available trial reports but incompletely or not
in a way that allowed for meta-analysis (e.g., mixed
model analyses reported, no results per group,
missing control group results, difference in means
without the standard error, etc.).
 No protocol or registry entry was found. The
outcome was reported in the available trial
reports but not in a way that allowed for
meta-analysis.
4. Unable to distinguish between selective reporting
and inadequate planning
 No protocol or registry entry was found and
the outcome was not reported in the available
trial reports.
5. Other situations
 The outcome was listed in the trial reports, but
there was no event (e.g., the outcome was death
but no death occurred).
 The outcome concerned adverse events, but
there was no event (e.g., the outcome was
“Major Complications—Visceral injury,” but no
complications were reported).
 The outcome was reported in the available trial
reports in a way that could allow for inclusion in
a meta-analysis but was not included in the
meta-analysis.
As a quality assessment measure, 10% of the RCTs
were classified independently by two reviewers (YY and
AD), with no disagreements.
Evaluation of research waste
Feasibility and cost of measuring the missing outcomes
that were not planned
To evaluate whether the missing outcomes that were not
planned could have been easily measured, we used an ex-
pert consensus approach. One of us (YY) presented to an
expert panel of five methodologists and trialists (AD, IB,
PC, PR, and VT) each RCT for which at least one missing
outcome was classified as not planned. After evaluating
standardized information on the population, interventions
in the experimental and control group, and other out-
comes evaluated, the panel of experts were asked to answer
the following questions regarding the missing outcomes:
 “According to you, given the other outcomes
measured in the trial, and based on your experience,
would you consider that measuring the presented
outcome would be easy, moderately easy, difficult
or impossible in most cases from a trialist’s
perspective?”
 “According to you, given the other outcomes
measured in the trial, and based on your experience,
would you consider that measuring the presented
outcome would be easy, moderately easy, difficult
or impossible in most cases from a patient’s
perspective?”
 “According to you, given the other outcomes
measured in the trial, and based on your experience,
what would be the approximate cost of measuring
this outcome: no cost defined as ≤ 1% of the total
cost of the trial; minor cost, defined as ≤ 5%;
moderate cost, 5% to 15%; or major cost, 15% or
more”. These percentages were indicative.
 “According to you, how important is the
missing outcome: major importance; non-major
importance?”
One of us (YY) ensured that all experts first gave their
opinion and then discussed together, to avoid the opin-
ion of one leading person influencing the others. The
final feasibility and cost evaluation of every proposed
adjustment was based on the group consensus.
The qualifications and areas of expertise of the experts
involved are summarized in Additional file 2.
Avoidable waste of research related to missing outcomes
We defined avoidable waste related to missing outcomes
as missing important outcomes related to:
 Selective reporting
 Incomplete reporting
 Inadequate planning, if the outcome was judged by
the expert panel as easy to collect from both the
trialist and patient perspective, not costly (i.e., no or
minor additional cost), and of critical importance
At the trial level, such waste could have been partially
avoided if the trial could have been included in the
meta-analysis of at least one missing outcome and totally
if it could have been included in all meta-analyses of
missing outcomes.
Statistical analysis
The analysis was mainly descriptive. Continuous data
are presented as median (Q1–Q3) and categorical data
as frequencies (%, 95% confidence interval [CI]). All
analyses involved use of R 3.0.2 (2013–09-25) (R
Foundation for Statistical Computing, Vienna, Austria.
http://www.r-project.org/).
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Results
Identification of RCTs excluded from meta-analyses
Selection and characteristics of the Cochrane systematic
reviews
The complete selection process is described in Fig. 1.
Briefly, from the 2796 Cochrane systematic reviews pub-
lished between March 2011 and September 2014, 820 re-
views corresponded to our eligibility criteria. Our
selection process resulted in a sample of 290 reviews
(5047 RCTs), with a median of 11 RCTs per review
(Q1–Q3: 5–21) (Fig. 1). The subset of included reviews
appeared comparable to the eligible Cochrane Reviews
(Additional file 3). The reviews investigated 47 different
health research topics, the most common being airways
(7%, n = 21/290), menstrual disorders and subfertility
(7%, n = 20/290), and anesthesia (6%, n = 18/290)
(Table 1). Experimental interventions were pharmaco-
logical in 60% of reviews (n = 175/290).
The reviews included a median of 5 outcomes per SoF
table for the main comparison (Q1–Q3: 3–7, Min–Max:
1–12), for a total of 1414 outcomes. Mortality repre-
sented 10% (n = 138/1414) of the outcomes, and other
clinical events, 14% (n = 198/1414); quality of life, 7%
(n = 98/1414); function, 27% (n = 384/1414); and adverse
events, 12% (n = 174/1414) (Table 1). Biological variables,
process and resource use, and physiological variables
accounted for 6% (n = 89/1414), 5% (n = 74/1414), and 4%
(n = 56/1414), respectively. The corresponding meta-ana-
lyses included a median of 3 RCTs (Q1–Q3: 2–7),
maximum 76.
Proportion of RCTs excluded from the meta-analyses due to
outcome reasons
The 290 reviews included a total of 2711 RCTs in the
main comparison; 596 (22%; 95% CI: 20–24) were in-
cluded in all meta-analyses of important outcomes, and
Fig. 1 Flow chart of the selection process. This figure summarizes the selection process for Cochrane reviews, RCTs, and outcomes. The analyzed
sample involved 290 Cochrane reviews, which included 2711 RCTs in the SoF table of the main comparison. The SoF tables reported 1414
important outcomes. RCT randomized controlled trial, SoF summary of findings
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2115 (78%, 95% CI: 76–80) were excluded from at least
one meta-analysis. Every RCT contributed to 55%, on
average, of the meta-analyses for important outcomes.
Evaluation of the reason for missing outcomes
Among the 2115 RCTs excluded from at least one
meta-analysis of important outcomes, 310 were pub-
lished in 2010 or later. We further excluded 19 RCTs,
because their reports were not accessible (e.g., retracted
paper) or were not in English or French (e.g., Chinese),
which left 291 RCTs for further evaluation, with a total
of 971 missing outcomes. A registration number or a
protocol was retrieved for 54% (n = 156/291) of these
RCTs (corresponding to 461 missing outcomes).
Reasons for missing outcomes were incomplete
reporting for 21% of missing outcomes (n = 204/971) in
40% of RCTs (n = 117/291), and inadequate planning for
29% of missing outcomes (n = 282/971) in 42% of RCTs
(n = 123/291) (Table 2). Confirmed selective reporting
represented 4% of missing outcomes (n = 36/971) in
9% of RCTs (n = 25/291). Nevertheless, 42% of RCTs
(n = 122/291) had no protocol or registration, so for
these, we could not distinguish between selective report-
ing and inadequate planning.
When restricting our description to registered RCTs
(n = 156), inadequate planning concerned 61% of missing
outcomes (n = 282/461) in 79% of RCTs (n = 123/156),
whereas incomplete reporting accounted for 21% of missing
outcomes (n = 98/461) in 41% of RCTs (n = 64/156), and
selective reporting, 7% of missing outcomes (n = 34/461) in
15% of RCTs (n = 23/156) (Table 2).
Evaluation of research waste
Feasibility of measuring the missing outcomes that were
not planned
We submitted the 282 outcomes missing due to inad-
equate planning from 123 RCTs to our panel of experts.
For 78% of outcomes (n = 221/282), the experts judged
the outcome of critical importance given the context.
For these 221 critically important outcomes, they con-
sidered that 82% (n = 182) could have been easily mea-
sured from both the trialist and patient perspective at no
cost (Additional file 4).
Avoidable waste of research due to missing important
outcomes
For the 291 RCTs published in 2010 or later, taking into
account selective or incomplete outcome reporting,
waste of research could have been partially avoided for
43% (n = 126) and totally (i.e., the trial could have been
included in all meta-analyses of important outcomes) for
12% (n = 34) (Fig. 2). If we also consider missing out-
comes that could have been easily measured from the
planning stage at no additional cost as judged by our ex-
perts, waste of research could have been partially
avoided for 63% of RCTs (n = 183) and totally for 30%
(n = 86) (Fig. 2).
Table 1 Characteristics of selected systematic reviews
and outcomes
Review characteristics n = 290
Median (Q1–Q3)
No. of trials per review 11 (5–21)
No. of trials in the main comparison 5 (3–12)
No. of comparisons per review 2 (1–5)
Cochrane review groups n = 290
No. (%)
Airways 21 (7)
Menstrual disorders and subfertility 20 (7)
Anesthesia 18 (6)
Oral health 15 (5)
Schizophrenia 15 (5)
Hepato-biliary 12 (4)
Neuromuscular disease 12 (4)
Musculoskeletal 11 (4)
Infectious diseases 10 (3)
Other 156 (54)




Outcomes characteristics n = 141
No. of outcomes per SoF table, median (Q1–Q3) 5 (3–7)
No. of trials per meta-analysis, median (Q1–Q3) 3 (2–7)
Outcome categories n = 1414
No. (%)*
Function 384 (27)
Other clinical events 198 (14)
Adverse events; side effects 174 (12)
Mortality 138 (10)
Quality of life 98 (7)
Biological variables 89 (6)
Process, resource use 74 (5)
Pain 71 (5)
Physiological variables 56 (4)
Compliance 45 (3)
Therapeutic decision 33 (2)
Satisfaction with care 24 (2)
Radiological variables 23 (2)
Cost-effectiveness 16 (1)
*The total exceeds 100% because some outcomes were included in more than
one category
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Discussion
We evaluated the avoidable waste of research due to
outcome-related reasons across a large number of RCTs
included in recent Cochrane systematic reviews in a var-
iety of medical fields. Our analysis revealed that 78% of
the RCTs were not included in all meta-analyses of im-
portant outcomes and that every RCT contributed to 55%,
on average, of the meta-analyses of these important out-
comes. Among registered RCTs, inadequate planning was
the most common reason affecting 79% of RCTs with
missing outcomes. Such waste could have been partially
avoided for 63% of the RCTs and totally for 30%.
Our findings suggest that many RCTs were not included
in all meta-analyses of important outcomes and that every
RCT contributed to only half of the meta-analyses, on
average. These results seem consistent with the literature.
In a recent study of patient-important outcomes, the me-
dian proportion of trials included in a meta-analysis for
such outcomes was about 60% [39]. Approximately half of
the RCTs included in another sample of Cochrane reviews
were included in the pooled effect size estimates in
the meta-analyses of patient-important outcomes [40],
whereas more than one-third of the outcomes pre-
specified in the review were not reported in the re-
sults sections [18, 41].
Although possible reasons for excluding RCTS from
meta-analyses have been hypothesized, the respective
contribution of inadequate planning and selective
reporting or incomplete reporting was unknown. Our
results provide major insights into this question, show-
ing that many RCTs do not plan the most important
outcomes to evaluate. Inadequate planning represents a
missed opportunity within a trial because equipoise re-
mains unchanged after this trial. However, a missed op-
portunity at the trial level will result in waste of research
at the meta-analysis level. Actually, clinical research
should be considered a sequential process, with each
new trial contributing to the existing body of evidence.
If a trial fails to do so because of a missed opportunity,
it becomes a source of waste of research and resources
at the meta-analysis level because this trial will not con-
tribute to the overall evidence. Cochrane reviewers may
select outcomes that differ in importance from those se-
lected by trialists (typically those defined as primary out-
comes and used for sample size calculation). Trialists
rarely consider adverse events (particularly severe
adverse events) as primary outcomes and for sample size
calculation. However, these outcomes are crucial to
assess and report because they could be included in
meta-analyses to increase power and inform decision-
making. Identifying important outcomes is challenging,
and without a consensus on outcomes, heterogeneity in
outcomes evaluated will remain [41].
To overcome these issues, several initiatives have
emerged to improve the relevance and consistency of
outcomes used in clinical research [4, 42–45]; one is the
Core Outcome Measures in Effectiveness Trials
(COMET) initiative promoting the development and use
of standardized core outcome sets (COSs). COMET of-
fers extremely helpful tools for researchers aiming to de-
velop COSs in their fields. However, although the
number of COSs is rapidly increasing, it remains limited
[46–48], and searching for specific existing COSs for a
given condition is difficult. The COMET website may
evolve to present available COSs in a tabular fashion to
help trialists identify the outcomes to use and re-
searchers the conditions for which COSs are needed.
Another perspective would be to use the outcomes re-
ported in the SoF table of Cochrane reviews to develop
COSs, because most of these outcomes seem important
to patients.
Incomplete reporting was another common reason for
outcomes excluded from meta-analyses. Two main situa-
tions can be distinguished. First, the failure to report re-
sults adequately (e.g., reporting means without standard
deviations) and second, the reporting of an analysis that
cannot be included as such in a meta-analysis (e.g.,
reporting of repeated data analysis). The first situation
is clearly related to poor reporting. We previously
showed that results were more completely reported at
Table 2 Classification of reasons for missing outcomes
All trials published in 2010 or later
Reasons for missing outcome All trials (registered and unregistered) Registered trials
No. of affected outcomes (%)
N = 971
No. of affected trials (%)*
N = 291
No. of affected outcomes (%)
N = 461
No. of affected trials (%)*
N = 156
Inadequate planning 282 (29) 123 (42) 282 (61) 123 (79)
Selective reporting 36 (4) 25 (9) 34 (7) 23 (15)
Incomplete reporting 204 (21) 117 (40) 98 (21) 64 (41)
Unable to distinguish between
selective reporting and lack
of planning
363 (39) 122 (42)
Other situations 86 (9) 63 (24) 47 (10) 41 (26)
*The total exceeds 100% because some outcomes were included in more than one category
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ClinicalTrials.gov than in publications, probably be-
cause of the standardized template used to report re-
sults at ClinicalTrials.gov [49]. Such standardized
templates may help trialists determine which data
should be reported and should be included in report-
ing guidelines and required by journals to improve
the presentation of results. The other situation is
more complex because it does not reflect poor
reporting, just reporting in a different way. Studies
with repeated data are meant to record measurements
at numerous time points to inform researchers of
changes over time. However, several approaches for
meta-analyzing these types of data exist, and they can
differ in terms of the data needed for analysis [50].
Therefore, reporting trial results not just for an im-
mediate use but also considering a later inclusion in
(I). initially (II). after accounting 
for selective or 
incomplete reporting,
(III). after accounting 
for selective or 
incomplete reporting
and lack of planning
Fig. 2 Avoidable waste of research related to missing outcomes in RCTs published in 2010 or later and not contributing to all meta-analyses of
important outcomes (n = 291). This figure summarizes the evolution of the outcomes status of SoF tables (O1 to O12 because SoF tables included
from 1 to 12 outcomes per review) for each RCT at the different steps of our study: step I (i.e., information as it was extracted), step II (i.e., after
evaluating the reason for the missing outcome) and after considering if there was no selective reporting or incomplete reporting, and finally step
III (i.e., evaluation of waste of research) and after accounting for inadequate planning and selective reporting or incomplete reporting (i.e., adequate
planning and no selective reporting or incomplete reporting). On the y-axis, each line represents one of the 291 RCTs published in 2010 or later and
not contributing to all meta-analyses of the outcomes reported in the SoF table. The x-axis represents the outcomes reported in the SoF table. Each
brick represents a single outcome of the SoF table. The color is a visual representation of the presence or absence of the outcome in the RCT. Light
blue means that the outcome was present in the corresponding RCT and dark blue that the outcome was absent in the RCT. RCT randomized
controlled trial, SoF summary of findings
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meta-analyses can be challenging. The Instrument for
reporting of Planned Endpoints in Clinical Trials
(InsPECT) reporting guidelines (currently under de-
velopment, https://www.inspect-statement.org/) might
help trial authors mitigate the effects of incomplete
reporting in RCTs.
Finally, selective reporting of outcomes seems to affect
a few trials. It remains an important issue in clinical tri-
als, with, on average, one-third of discrepancies in pri-
mary outcomes between protocols and publications [29]
or between registry information and publications [31]. In
our situation, this concerns only outcomes that were
planned and not reported at all in publications. Actually,
reviewers consider a given outcome whether this out-
come is reported as a primary or a secondary outcome.
Strengths and limitations of the study
In this study, we used an original approach to evaluate
the main reasons why a trial was not included in a
meta-analysis and the part of this waste that could be
avoided. We analyzed a large set of trials included in a
vast, unselected, sample of recent Cochrane reviews ex-
ploring various health-care research topics. Assembling
numerous experts in such a variety of fields to identify
the most important outcomes to evaluate would have
been challenging. As a proxy, we used the outcomes re-
ported in the SoF tables that were considered by the re-
view authors as the most important to measure for a
given comparison in a particular health condition [7].
We used the consensus of an expert panel of recognized
methodologists and trialists to assess the feasibility and
costs of measuring the missing outcomes. To avoid over-
estimating waste of research, we also asked the panel to
evaluate the importance of outcomes and considered
that research was wasted for only those outcomes the
panel confirmed to be of critical importance.
Our study has several limitations. First, we focused
only on trials included in Cochrane reviews published
between 2010 and 2014. However, it has been reported
that Cochrane and non-Cochrane reviews have systemic
differences, likely reflective of different methodology
[51]. Then, we focused on trials included in the reviews
but excluded from at least one meta-analysis. We did
not consider the number of trials excluded from the re-
views for outcome-related reasons. Therefore, we prob-
ably underestimated the proportion of trials excluded
from meta-analyses for outcome-related reasons. Despite
the recommendation of the Cochrane Handbook to de-
termine trial eligibility independently of outcomes mea-
sured (studies should not be excluded just because they
provide no usable data), some trials may be excluded for
this reason [7]. Thus, although, our sample of RCTs was
from a large variety of medical fields, the database used
(Cochrane reviews published between 2010 and 2014
and with an SoF table), the limited sample size, the lan-
guage restrictions, or the expertise of our panel of ex-
perts may limit the generalizability of our results.
Finally, as a quality measure, 10% of the RCTs were clas-
sified independently by two reviewers, since this assess-
ment is challenging and implies some subjectivity.
Conclusions
Our study shows that most RCTs included in our sample
of Cochrane reviews did not contribute to all meta-ana-
lyses of the most important outcomes mainly because of
inadequate planning or incomplete reporting. Such
waste could have been partially avoided for 63% of the
trials and totally for 30%. We need to accelerate the de-
velopment and dissemination of COSs and reduce poor
outcome reporting to avoid this waste.
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